Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes

Journal of Diabetes and its Complications

Volumn 23, Issue 2, 2009, Pages 143-152

  Caballero, A Enrique ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Insulin; Obesity; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; PLACEBO; SULFONYLUREA;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; DIABETIC DIET; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; GLYCEMIC CONTROL; HUMAN; INFORMATION RETRIEVAL; INSULIN TREATMENT; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EXERCISE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NUTRITIONAL STATUS; OBESITY; OVERWEIGHT;

EID: 59949100392     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.06.002     Document Type: Review

References (90)

1. Alvarsson M., Sundkvist G., Lager I., Henricsson M., Berntorp K., Fernqvist-Forbes E., Steen L., Westermark G., Westermark P., Orn T., and Grill V. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26 (2003) 2231-2237
2. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update. Endocrine Practice 8 Suppl. 1 (2002) 40-82
3. American Association of Clinical Endocrinologists. Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position statement, February 2, 2005 (2005). http://www.aace.com/pub/pdf/guidelines/OutpatientImplementationPositionS tatement.pdf (accessed on March 14, 2005)
4. American Diabetes Association. Diabetes and cardiovascular (heart) disease. Available at: (2002). http://www.diabetes.org/diabetes-statistics/heart-disease.jsp (accessed on February 13, 2007)
5. American Diabetes Association. National diabetes fact sheet. Prevalence of total diabetes in the United States, all ages-United States, 2002. Available at: (2002). http://www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet .jsp (accessed on February 13, 2007)
6. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 27 Suppl. 1 (2004) S11-S14
7. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 28 Suppl. 1 (2005) S4-S36
8. American Diabetes Association. The basics of insulin. Available at: (2005). http://www.diabetes.org/type-1-diabetes/basics.jsp (accessed on January 12, 2005)
9. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., and Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006) 2632-2637
10. Becker R.H., Frick A.D., Burger F., Potgieter J.H., and Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Experimental and Clinical Endocrinology & Diabetes 113 (2005) 435-443
11. Bell D.S., and Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocrine Practice 8 (2002) 271-275
12. Bohannon N.J.V. Optimizing insulin regimens in type 1 diabetes: How to help patients get control of their life. Postgraduate Medicine 113 (2003) 39-54
13. Boulé N.G., Haddad E., Kenny G.P., Wells G.A., and Sigal R.J. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. Journal of the American Medical Association 286 (2001) 1218-1227
14. Boulé N.G., Kenny G.P., Haddad E., Wells G.A., and Sigal R.J. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus. Diabetologia 46 (2003) 1071-1081
15. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
16. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obesity Research 11 (2003) 1278-1289
17. Caballero A.E. Endothelial dysfunction, inflammation, and insulin resistance: A focus on subjects at risk for type 2 diabetes. Current Diabetes Reports 4 (2004) 237-246
18. Caballero A.E. Diabetes in minorities in the United States. In: Kahn C.R., Weir G.C., King G.L., et al. (Eds). Joslin's diabetes mellitus. 14th ed. (2005), Lippincott Williams & Wilkins, Philadelphia, PA 505-524
19. Caballero A.E., Arora S., Saouaf R., Lim S.C., Smakowski P., Park J.Y., King G.L., Logerfo F.W., Horton E.S., and Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48 (1999) 1856-1862
20. Dandona P., Aljada A., Mohanty P., Ghanim H., Hamouda W., Assian E., and Ahmad S. Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect?. Journal of Clinical Endocrinology and Metabolism 86 (2001) 3257-3265
21. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine 131 (1999) 281-303
22. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., and Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
23. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. Journal of the American Medical Association 289 (2003) 2254-2264
24. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Annals of Neurology 38 (1995) 869-880
25. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 346 (2002) 393-403
26. Duman B.S., Turkoglu C., Gunay D., Cagatay P., Demiroglu C., and Buyukdevrim A.S. The interrelationship between insulin secretion and action in type 2 diabetes mellitus with different degrees of obesity: Evidence supporting central obesity. Diabetes Nutrition & Metabolism 16 (2003) 243-250
27. Eizirik D.L., Korbutt G.S., and Hellerström C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the β-cell function. Journal of Clinical Investigation 90 (1992) 1263-1268
28. European Diabetes Policy Group 1999. A desktop guide to Type 2 diabetes mellitus. Diabetic Medicine 16 (1999) 716-730
29. Expert Panel on Detection. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 285 (2001) 2486-2497
30. Field A.E., Coakley E.H., Must A., Spadano J.L., Laird N., Dietz W.H., Rimm E., and Colditz G.A. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Archives of Internal Medicine 161 (2001) 1581-1586
31. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27 (2004) 2444-2449
32. Franz M.J., Bantle J.P., Beebe C.A., Brunzell J.D., Chiasson J.L., Garg A., Holzmeister L.A., Hoogwerf B., Mayer-Davis E., Mooradian A.D., Purnell J.Q., and Wheeler M. Nutrition principles and recommendations in diabetes. Diabetes Care 27 Suppl. 1 (2004) S36-S46
33. Gæde P., Vedel P., Parving H.-H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353 (1999) 617-622
34. Genuth S. Insulin use in NIDDM. Diabetes Care 13 (1990) 1240-1264
35. Goldstein B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. American Journal of Cardiology 90 Suppl. (2002) 3G-10G
36. Gottesman I. Managing obesity and glycemic control in insulin-using patients: Clinical relevance and practice recommendations. Diabetes Research and Clinical Practice 65 Suppl (2004) S17-S22
37. Grundy S.M. Obesity, metabolic syndrome, and cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 89 (2004) 2595-2600
38. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., and Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109 (2004) 433-438
39. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., and Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Annals of Internal Medicine 143 (2005) 559-569
40. Henry R.R., and Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 14 (1991) 802-823
41. Hermansen K., Fontaine P., Kukolja K.K., Peterkova V., Leth G., and Gall M.-A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 (2004) 622-629
42. Hershon K.S., Blevins T.C., Mayo C.A., and Rosskamp R. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocrine Practice 10 (2004) 10-17
43. Hu F.B., Stampfer M.J., Haffner S.M., Solomon C.G., Willett W.C., and Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25 (2002) 1129-1134
44. Karter A.J., Mayer-Davis E.J., Selby J.V., D'Agostino R.B., Haffner S.M., Sholinsky P., Bergman R., Saad M.F., and Hamman R.F. Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes 45 (1996) 1547-1555
45. Katzmarzyk P.T., Church T.S., and Blair S.N. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Archives of Internal Medicine 164 (2004) 1092-1097
46. Katzmarzyk P.T., Church T.S., Janssen I., Ross R., and Blair S.N. Metabolic syndrome, obesity, and mortality: Impact of cardiorespiratory fitness. Diabetes Care 28 (2005) 391-397
47. Klein S., Sheard N.F., Pi-Sunyer X., Daly A., Wylie-Rosett J., Kulkarni K., and Clark N.G. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: Rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. American Journal of Clinical Nutrition 80 (2004) 257-263
48. Laakso M. Hypertension and macrovascular disease-The killing fields of NIDDM. Diabetes Research and Clinical Practice 39 Suppl. (1998) S27-S33
49. Lantus [package insert] (2004), Aventis Pharmaceuticals, Kansas City, MO
50. Larger E., Rufat P., Dubois-Laforgue D., and Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. Diabetes Care 24 (2001) 1849-1850
51. Lee Y., Hirose H., Ohneda M., Johnson J.H., McGarry J.D., and Unger R.H. β-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-β-cell relationships. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 10878-10882
52. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., Cordoni C., Costa E., Brunetti P., and Bolli G.B. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
53. LEVEMIR [package insert] (2005), Novo Nordisk, Princeton, NJ
54. Mäkimattila S., Nikkilä K., and Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 42 (1999) 406-412
55. Malmberg K., and for the DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314 (1997) 1512-1515
56. Mason T.M., Goh T., Tchipashvili V., Sandhu H., Gupta N., Lewis G.F., and Giacca A. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 48 (1999) 524-530
57. Mayfield J.A., and White R.D. Insulin therapy for type 2 diabetes: Rescue, augmentation, and replacement of beta-cell function. American Family Physician 70 (2004) 489-500
58. Meneghini L.F., Rosenberg K.H., Koenen C., Merilainen M.J., and Luddeke M.J. Insulin determir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDECTIVE study. Diabetes Obes Metab 9 3 (2007) 418-427
59. Messerli F.H., Christie B., DeCarvalho J.G., Aristimuno G.G., Suarez D.H., Dreslinski G.R., and Frohlich E.D. Obesity and essential hypertension: Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Archives of Internal Medicine 141 (1981) 81-85
60. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., and Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Journal of the American Medical Association 289 (2003) 76-79
61. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., and Dietz W.H. The disease burden associated with overweight and obesity. Journal of the American Medical Association 282 (1999) 1523-1529
62. 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23 (2000) 813-819
63. Pan X.-R., Li G.-W., Hu Y.-H., Wang J.X., Yang W.Y., An Z.X., Hu Z.X., Lin J., Xiao J.Z., Cao H.B., Liu P.A., Jiang X.G., and Jiang Y.Y. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544
64. Pick A., Clark J., Kubstrup C., Levisetti M., Pugh W., Bonner-Weir S., and Polonsky K.S. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47 (1998) 358-364
65. Raskin P., Klaff L., Bergenstal R., Halle J.-P., Donley D., and Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23 (2000) 1666-1671
66. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., and Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
67. Reichard P., Nilsson B.-Y., and Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine 329 (1993) 304-309
68. Riddle M.C., Rosenstock J., Gerich J., and for the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
69. Rolla A. The pathophysiological basis for intensive insulin replacement. International Journal of Obesity 28 Suppl. 2 (2004) S3-S7
70. Rosenstock J., Schwartz S.L., Clark C.M.J., Park G.D., Donley D.W., and Edwards M.B. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
71. Rossetti P., Pampanelli S., Fanelli C., Porcellati F., Costa E., Torlone E., Scionti L., and Bolli G.B. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 26 (2003) 1490-1496
72. Sigal R.J., Kenny G.P., Wasserman D.H., and Castaneda-Sceppa C. Physical activity/exercise and type 2 diabetes. Diabetes Care 27 (2004) 2518-2539
73. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
74. Tenenbaum A., Motro M., Schwammenthal E., and Fisman E.Z. Macrovascular complications of metabolic syndrome: An early intervention is imperative. International Journal of Cardiology 97 (2004) 167-172
75. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. New England Journal of Medicine 342 (2000) 381-389
76. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: A randomized, controlled trial. Annals of Internal Medicine 128 (1998) 517-523
77. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
78. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., Keinanen_Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., Salminen V., and Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine 344 (2001) 1343-1350
79. Turner R.C., Cull C.A., Frighi V., Holman R.R., and for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). Journal of the American Medical Association 281 (1999) 2005-2012
80. Turner R.C., and Holman R.R. The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group. Annals of Medicine 28 (1996) 439-444
81. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
82. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
83. Unger R.H., and Zhou Y.-T. Lipotoxicity of β-cells in obesity and in other causes of fatty acid spillover. Diabetes 50 Suppl. 1 (2001) S118-S121
84. Vague P., Selam J.-L., Skeie S., De Leeun I., Elte J.W.F., Haahr H., Kristensen A., and Draeger E. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-596
85. 1C and body weight in type 2 diabetes: Results of a 1.5-year follow-up study. Diabetes Research and Clinical Practice 61 (2003) 13-19
86. Weyer C., Bogardus C., Mott D.M., and Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Journal Clinical Investigation 104 (1999) 787-794
87. Wilson P.W., D'Agostino R.B., Sullivan L., Parise H., and Kannel W.B. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Archives of Internal Medicine 162 (2002) 1867-1872
88. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holman R.R., and for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
89. Yale J.-F., Valiquett T.R., Ghazzi M.N., Owens-Grillo J.K., Whitcomb R.W., and Foyt H.L. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: A multicenter, randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 134 (2001) 737-745
90. Yki-Järvinen, Hänninen H., Hänninen J., Hulme S., et al. Treat to Target simply-The LANMET study. Abstract presented at the American Diabetes Association 64th Annual Scientific Sessions, Orlando, FL, June 4-8, 2004 (Abstract 2181-PO) (2004)